In a groundbreaking leap for cardiovascular research, scientists have engineered self-assembled chamber-like cardiac organoids that faithfully mimic the complex architecture and functionality of human heart chambers. This pioneering development not only provides a transformative model for studying cardiac chamber formation but also establishes a robust platform for assessing drug-induced cardiotoxicity, potentially revolutionizing how new therapeutics are evaluated before clinical trials. Published this year in Nature Communications, the work by Zou, Wang, Zheng, and colleagues spotlights the convergence of stem cell biology, tissue engineering, and regenerative medicine, presenting an unprecedented window into the earliest steps of heart development and disease modeling.

The human heart’s intricate structure—comprising multiple chambers each with specialized functions—is notoriously challenging to replicate in vitro. Traditional two-dimensional cardiomyocyte cultures lack the spatial organization and mechanical cues necessary for proper cardiac maturation. While previous three-dimensional cardiac organoids have demonstrated contractile activity and cell heterogeneity, recreating chamber-like structures that resemble true heart morphology has remained elusive. Zou et al. surmount this hurdle by harnessing self-assembly principles, enabling pluripotent stem cells to organize autonomously into defined, chambered organoids. This architectural mimicry is essential, as the heart’s ability to pump blood relies heavily on the precise formation and interplay of distinct chambers.

Central to their approach is the optimization of culture conditions that guide stem cells down specific differentiation trajectories while promoting cellular interactions and biomechanical feedback mechanisms. Through a carefully orchestrated protocol, the research team modulated signaling pathways such as Wnt, BMP, and Notch, which are pivotal during embryonic heart development. This biochemical guidance, combined with tailored extracellular matrix components, facilitated the aggregation of cardiomyocytes, cardiac fibroblasts, and endothelial cells into a cohesive, hollow structure reminiscent of heart chambers. Notably, the organoids exhibited spontaneous contractions with coordinated electrical conduction, underscoring their functional maturity.

This model opens unprecedented avenues for interrogating the molecular and biomechanical determinants of cardiac chamber morphogenesis. Researchers can now probe how gradients of morphogens and mechanical forces sculpt chamber identity, valve formation, and myocardial patterning in a controlled laboratory environment. By recapitulating key developmental milestones in vitro, these organoids provide insight into congenital heart defects and allow for the dissection of complex gene-environment interactions that underlie cardiac malformations. The study paves the way for elucidating pathway-specific perturbations linked to heart disease.

In addition to developmental insights, the chamber-like organoids serve as a sophisticated platform for pharmacological screening. Drug-induced cardiotoxicity remains a pervasive challenge in drug development, often causing late-stage failures or post-market withdrawals. Current preclinical models, including animal testing and 2D cultures, only partially recapitulate human cardiac physiology, limiting predictive accuracy. These self-assembled cardiac organoids, by contrast, provide a human-relevant context to assess the electrophysiological, structural, and contractile effects of novel compounds, capturing subtle toxicities that conventional assays might overlook.

The research team demonstrated the utility of their platform by testing well-known cardiotoxic agents, revealing dose-dependent disruptions in organoid rhythm and contractile force. Their findings correlated with clinical manifestations observed in patients, suggesting that this model can forecast adverse cardiac responses with enhanced fidelity. This capability could streamline drug safety assessments, reduce reliance on animal models, and ultimately expedite the delivery of safer cardiovascular therapeutics to patients.

Crucially, the organoids produced by Zou et al. display remarkable reproducibility and scalability, addressing long-standing challenges in organoid research. By standardizing the self-assembly process, the team ensured consistent formation of chambers exhibiting uniform size, morphology, and cell composition across batches. This consistency lays the groundwork for larger-scale applications such as high-throughput drug screening and precision medicine initiatives, where patient-derived organoids could be tested against personalized therapeutic regimens.

Furthermore, the researchers leveraged advanced imaging and electrophysiological techniques to characterize organoid dynamics in real time. Using high-resolution confocal microscopy and multi-electrode arrays, they mapped calcium transients, electrical propagation, and mechanical contraction patterns within the chamber-like structures. These comprehensive analyses confirmed that the organoids not only structurally resemble heart chambers but also functionally emulate their synchronous beating and electrical coupling, hallmarks of a physiologically relevant cardiac model.

Beyond drug testing, the potential of these cardiac organoids extends into regenerative medicine. The ability to self-organize into chambered constructs suggests their suitability for bioengineered tissue grafts aimed at repairing damaged myocardium. Although clinical translation remains distant, the mechanistic insights gained from these models can inform strategies for enhancing cardiac regeneration, integrating stem cell therapies, and engineering next-generation heart patches.

Zou and colleagues also touched upon the ethical and logistical advantages of their organoid system. By reducing dependence on animal experimentation, their model aligns with the principles of the 3Rs (replacement, reduction, refinement) in biomedical research. Additionally, the use of human induced pluripotent stem cells enables studies on genetically diverse populations, enhancing our understanding of how individual genetic backgrounds influence heart development and drug responses.

The combination of bioengineering, developmental biology, and pharmacology embodied in this research illustrates a paradigm shift in cardiovascular science. Where once the heart was an impenetrable black box, the creation of chamber-like cardiac organoids offers a tangible window into its formation, function, and pathologies. This synthetic heart tissue platform promises to accelerate the discovery of novel treatments for heart disease, a leading cause of mortality worldwide, with profound implications for public health.

Looking forward, the research sets the stage for integrating other cell types critical to heart function, such as immune cells and specialized conduction system components, to achieve even more physiologically comprehensive organoids. Advances in microfluidics and tissue perfusion could further enhance nutrient delivery and waste removal, mimicking in vivo conditions and prolonging organoid survival. Such innovations will push the boundaries of what organoids can reveal about cardiac biology and therapeutic potential.

In summary, the self-assembled chamber-like cardiac organoids developed by Zou et al. represent an extraordinary technological and conceptual advance. By recapitulating the form and function of human cardiac chambers in vitro, they provide a powerful tool for unraveling the complexities of heart development and disease, enabling safer drug discovery, and opening new horizons for regenerative therapies. This landmark study heralds a new era in cardiovascular research where the heart’s mysteries can be explored with unprecedented clarity, precision, and relevance.

---

Subject of Research: Cardiac development, cardiac organoids, cardiotoxicity assessment, tissue engineering.

Article Title: Self-assembled chamber-like cardiac organoids for modeling cardiac chamber formation and cardiotoxicity assessment.

Article References:
Zou, X., Wang, F., Zheng, H. et al. Self-assembled chamber-like cardiac organoids for modeling cardiac chamber formation and cardiotoxicity assessment. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73822-6

Image Credits: AI Generated

The video by Aboriginal artist Carolyn Windy, shared by Bible Society Australia, illustrates God's creation and salvation message.

The heart transcends its role as a mere blood pump; it is the center of love, thought, and soul. Biblical references affirm its significance in emotions and spirituality, suggesting it embodies much more than physical function.

When most people think of visual art, they don’t usually think of math at the same time. One primary reason for this is that mainstream culture has framed art and math as two separate functions of the brain.

However, because the brain works as a whole when creating art and solving mathematical problems, a new study suggests that abstract art may follow hidden mathematical principles that influence how people perceive and respond to it.

For years, researchers have wondered why certain types of art move people more than others. Until now, however, there has been no direct explanation.

Using a sophisticated method from computational topology, researchers discovered that famous abstract artists appear to share a common structural pattern in their work. Researchers are calling this a mathematical “golden rule” that can distinguish real art from AI-generated “slop.”

Led by Jacek Rogala of the University of Warsaw and Shabnam Kadir of the University of Hertfordshire, the research team used a technique called persistent homology to analyze visual compositions. Persistent homology is a mathematical tool that breaks down how structures within an image change across multiple scales, revealing patterns that the human eye cannot see.

Patterns Hidden in Abstract Imagery

The team compared two sets of images: authentic abstract paintings created by celebrated artists such as Wassily Kandinsky, Mark Rothko, and Jackson Pollock, and “pseudo-art” produced by AI to mimic abstract styles.

The findings suggested the topological method could distinguish real art from AI-generated images. According to the researchers, the structural organization of authentic paintings changed in consistent, measurable ways compared to the computer-generated alternatives.

Senior author Jacek Rogala said in a statement, “What struck me most is that we could actually see the gallery environment doing something measurable. It wasn’t just a backdrop — it changed which images held attention and for how long. That’s a result you can put numbers on, and it still feels surprising.”

When examining the works of Wassily Kandinsky, Mark Rothko, and Jackson Pollock more closely, the researchers discovered that the artists’ paintings tended to converge on a similar rate of violation of a mathematical relationship called Alexander duality. This concept describes the balance between structures near the edges of an image and what is happening in the middle.

“An important part of our study was to explore the relationship between topologically derived image features, eye movement, and aesthetic experience,” the authors say in a co-statement. “Our research showed that our newly developed method not only clearly distinguished between two sets of images but also allowed us to map topological features onto gaze fixation heat maps.”

The Hidden Mathematics Behind Works of Art

Researchers think many abstract artists may naturally arrange shapes and patterns in similar ways, even without knowing the mathematics behind them. This hidden structure could help explain why certain artworks feel more pleasing or emotionally engaging to viewers.

The researchers also took the study a step further by examining how people respond physically and mentally to abstract art. Participants studied both authentic and AI-generated images while researchers tracked their eye movements and monitored brain activity in laboratory and gallery settings. The results revealed noticeable behavioral differences. Real artworks produced more stable, integrated patterns of brain activity, while AI-generated art elicited more exploratory eye movements.

Overall, the study suggests that abstract art is not purely subjective or random. Instead, abstract art may follow hidden mathematical patterns that naturally connect with the way our brains interpret and understand images.

The study, “Art’s Hidden Topology: A Window into Human Perception,” was published in PLOS Computational Biology.

Chrissy Newton is a PR professional and the founder of VOCAB Communications. She currently appears on The Discovery Channel and Max and hosts the Rebelliously Curious podcast, which can be found on YouTube and on all audio podcast streaming platforms. Follow her on X: @ChrissyNewton, Instagram: @BeingChrissyNewton, and chrissynewton.com. To contact Chrissy with a story, please email chrissy @ thedebrief.org.

Neuralink’s first female PRIME trial participant, Audrey Crews, is now creating abstract art using the company’s brain-computer interface.

Crews, who was paralyzed from the neck down at age 16, has been creating memorable abstract art with her mind using an innovative brain-computer interface (BCI) technology.

Crews is the 9th Neuralink participant and the first woman to receive the implantable device in the PRIME clinical trials.  

With fewer than 100 people worldwide with BCIs, Crews has found herself at the intersection of art and the future of bneuroscience. By using only the power of thought, Crews has created vibrant abstract art with rich color and shapes.

On her website, she explains why creating this art is important to her: “My mission is to expand the boundaries of human expression and share the u

nseen landscapes of the mind,” Crews says. 

Her artwork has evolved stylistically since her first showcase on X in 2025, at which time she was learning to draw her name.

“I tried writing my name for the first time in 20 years. Im working on it,” Crews said in a post on X. 

“I’ll never forget the moment I used my thoughts to write my name, ‘Audrey,’ on a laptop screen for the first time in two decades. I even drew hearts and a slice of pizza, which felt like a small miracle! I shared that moment on X, laughing about my progress,” Crews said on her website.

“It’s humbling to know my journey is helping Neuralink refine this technology, which could one day let millions control devices with their minds,” she added.  

Since then, Crews’ art has evolved, and she has also launched her online NeuraArt Studio, where fans can purchase limited-edition prints of her artwork.

Amid the BCI company’s efforts, Neuralink states that its devices are still “investigational and not FDA approved.” 

However, in January of this year, the company said in a statement that a “primary ‌aim of our expanding clinical trials is to better understand these variations and improve both our hardware and the overall procedure for every participant.”

Neuralink began human trials of its brain implant in 2024 after resolving safety concerns raised by the U.S. Food and Drug Administration, which had previously declined to approve its initial application in 2022.

For Crews, what she has achieved lies at the intersection of current implantable BCI technology and fine abstract art, signaling a fundamental reframing of what it means to create, perceive, and even experience such creative products—a shift from something merely observed to something partially constructed by BCI users through thought.

“This breakthrough didn’t just restore my ability to create—it ignited a passion for art that had been dormant for too long,” she says. Crews’ art can be viewed, and prints are available for purchase, on her NeuraArt Studio website.

Chrissy Newton is a PR professional and the founder of VOCAB Communications. She currently appears on The Discovery Channel and Max and hosts the Rebelliously Curious podcast, which can be found on YouTube and on all audio podcast streaming platforms. Follow her on X: @ChrissyNewton, Instagram: @BeingChrissyNewton, and chrissynewton.com. To contact Chrissy with a story, please email chrissy @ thedebrief.org.